Trending Topic

11 mins

Trending Topic

Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked

Lung cancer is the second most common type of cancer worldwide and in the USA, with its incidence varying depending on geographic and socioeconomic factors.1–3 According to data from the Global Cancer Observatory: Cancer Incidence, Mortality and Prevalence (GLOBACAN) database, an estimated 2.48 million new cases of lung cancer were reported in 2022.4,5 Although lung cancer rates in the […]

Jason Luke, ESMO 2021: Efficacy and Safety Results from the KEYNOTE-716 Double-blind Phase III Trial

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Published Online: Oct 5th 2021

touchONCOLOGY joins Dr Jason Luke (UPMC Hillman Cancer Center, PA, USA) at ESMO 2021 to discuss the efficacy and safety results from the KEYNOTE-716 double-blind phase III trial.

Questions
1. Patients with high-risk stage II melanoma are at significant risk of recurrence after surgical resection – what treatment options do these patients currently have to prevent recurrence? (00:16-01:30)
2. What was the rationale for investigating pembrolizumab in patients with high-risk stage II melanoma, in terms of previously demonstrated efficacy? (01:30-02:22)
3. Please outline the key objectives and methodology of the KEYNOTE-716 trial? (02:22-03:00)
4. What were the main efficacy and safety findings of the KEYNOTE-716 trial? (03:00-04:17)
5. How will these results impact the treatment of patients with high-risk stage II melanoma? (04:17-04:47)

Disclosures: Jason Luke has no financial or non-financial conflicts of interest to declare in relation to this video.

Support: Interview and filming supported by Touch Medical Media. Interview conducted by Sophie Nickelson.

Filmed in coverage of the ESMO 2021 Annual Meeting.

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Close Popup